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Neuroimagem do transportador de dopamina em casos de parkinsonismo clinicamente 
indefinidos e a importância dos SWEDDs (exames sem evidência de déficit dopaminérgico)
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The parkinsonian syndrome (PK) encompasses several 
well-known disorders, including (i) Parkinson’s disease (PD); 
(ii) parkinsonism secondary to non-degenerative causes; (iii) 
atypical degenerative parkinsonism; and (iv) heredodegenera-
tive parkinsonism1-3. In our service4, among patients with PK, 
three quarters of them receive the final diagnosis of PD (Fig 1).
The diagnosis of PD is essentially clinical and the most 
commonly used criteria (UK PDS Brain Bank) are based on 
three steps (Table 1)1,2. However, clinicopathologic studies 
have shown a high rate of false-positives and false-negatives1,5. 
Additionally, the seminal study by Braak and colleagues, 
showing that the pathological process starts at the brainstem 
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ABSTRACT
The clinical diagnosis of Parkinson’s disease (PD) is susceptible to misdiagnosis, especially in the earlier stages of the disease. Recently, in 
vivo imaging techniques assessing the presynaptic dopamine transporter (DAT) have emerged as a useful tool in PD diagnosis, improving 
its accuracy. Objective: It was to illustrate the clinical usefulness of a brain single-photon emission computed tomography (SPECT) DAT 
ligand, and highlight relevant aspects of scans without evidence of dopaminergic deficit (SWEDDs) in this context. Cases: We described four 
representative patients with clinically unclear parkinsonian syndromes who underwent [99mTc]-TRODAT-1 SPECT and reviewed the clinical 
implications. Conclusion: DAT-SPECT is an important, cost-effective, technique for the differential diagnosis of parkinsonian syndromes. 
Additionally, SWEDD cases present clinical and paraclinical peculiarities that may retrospectively identify them as essential/dystonic tremor. 
The lack of histopathological data limits further conclusions.
Key words: Parkinson disease, scans without evidence of dopaminergic deficit, tomography, emission-computed, single-photon, Tc-99m-
trodat-1, dopamine transporter.
RESUMO
O diagnóstico clínico da doença de Parkinson (DP) pode estar sujeito a erros especialmente nas fases iniciais da doença. Recentemente, técnicas 
de imagem in vivo que avaliam o transportador de dopamina pré-sináptico (DAT) surgiram como uma ferramenta empregada no diagnóstico da 
DP, melhorando sua acurácia. Objetivo: Foi demonstrar a utilização clínica de um traçador de tomografia computadorizada por emissão de fóton 
único (SPECT) e destacar importantes aspectos dos casos de SWEDDs (exames sem evidência de déficit dopaminérgico) neste contexto. Casos: 
Descrevemos quatro pacientes representativos de síndromes parkinsonianas clinicamente incertas submetidos a [99mTc]-TRODAT-1 SPECT e re-
visamos suas implicações. Conclusão: O DAT-SPECT é uma técnica importante e eficiente para o diagnóstico diferencial das síndromes parkinso-
nianas. Além disso, os casos de SWEDDs apresentam peculiaridades clínicas e paraclínicas que podem retrospectivamente identificá-los como 
tremor essencial ou tremor distônico. As conclusões têm alcance limitado pela falta de dados histopatológicos.
Palavras-Chave: doença de Parkinson, exames sem evidência de déficit dopaminérgico, tomografia computadorizada de emissão de fóton 
único, Tc-99m-trodat-1, transportador de dopamina.
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and olfactory nucleus, later involving the midbrain and sub-
stantia nigra, confirmed the perception that current diag-
nostic criteria, focusing on motor manifestations of PD, have 
limited sensitivity to identify the disease in its earliest stages6.
In order to improve the accuracy of in vivo diagnosis of 
PD, investigative efforts have focused on the detection of 
either structural changes in the substantia nigra or striatal 
dopaminergic function. While the pathological structural 
changes have been studied using transcranial ultrasound 
and magnetic resonance imaging (MRI) techniques, stri-
atal dopaminergic dysfunction can be assessed in three 
different ways: (1) evaluating the density of presynap-
tic dopamine transporters (DAT) using positron emis-
sion tomography (PET) or SPECT tracers; (2) measuring 
dopa decarboxylase enzyme activity as a marker for do-
pamine turnover using 18F-dopa PET; and (3) identify-
ing vesicular monoamine transporters type 2 with 11C- or 
18F-dihydrotetrabenazine PET7.
Additionally, there may be some 4 to 15% of patients 
considered to have PD, but who may indeed have normal 
scans or the so-called scans without evidence of dopami-
nergic deficit (SWEDD). This acronym is actually a radio-
logical term that arose from previous papers on the lit-
erature of clinical trials in PD, particularly the CALM-PD, 
REAL-PET and ELLDOPA studies8-11. Overall, SWEDD pa-
tients have signs of PK, but do not have PD, their striatal 
dopaminergic function seems normal and there is no clini-
cal response to levodopa12.
This paper aimed to illustrate the usefulness of DAT im-
aging using [99mTc]-TRODAT-1 SPECT, contextualized in the 
assessment of four clinical cases, and to review relevant as-
pects emerging from its use, which includes the dilemma of 
the cases with SWEDDs.
ILLUSTRATIVE CASES
Case 1
A 60-year-old female noticed difficulty with manipula-
tion of objects using her left hand. It started with progressive 
loss of left hand dexterity, severe enough to affect daily activi-
ties, during the previous year. She referred a depressed mood 
and lack of interest in previously pleasurable activities. There 
were no relevant comorbidities except for moderate obesity. 
She was physically inactive and a former smoker. Her mother 
had hypertension and suffered from an ischemic stroke.
Fig 1. Causes of parkinsonism. Final diagnoses from our 
movement disorders clinic as presented by Munhoz et al.4.  
All values are presented in percentages (n=1528).
PD 74.74
Other causes,
1.44
Infectious Pk,
0.46
Genetic Pk,
1.18 CBD, 0.39
LBD, 2.75
MSA, 3.40
PSP, 3.86
VP, 3.93
DIP, 7.85
PD: Parkinson’s disease; DIP: drug-induced parkinsonism; VP: vascular 
parkinsonism; PSP: progressive supranuclear palsy; MSA: multiple system atrophy; 
LBD: Lewy body dementia; CBD: corticobasal degeneration; PK: parkinsonism.
Table 1. The United Kingdom Parkinson’s Disease Society Brain Bank clinical diagnostic criteria.
Step 1. Diagnosis of Parkinsonism Step 2. Exclusion criteria for PD Step 3. Supportive criteria for PD  (≥3 required for definite diagnosis)
Bradykinesia(a) and ≥1 of the following:
Muscular rigidity;
4–6 Hz rest tremor;
Postural instability(b).
Repeated strokes with stepwise progression
Repeated head injury
Definite encephalitis
Oculogyric crises
Use of neuroleptic or dopamine-depleting 
agents at onset of symptoms
>1 affected relative
Sustained remission
Strictly unilateral features after 3 y
Supranuclear gaze palsy
Cerebellar signs
Early severe disautonomy
Early severe dementia with disturbances of 
memory, language or praxis
Babinski sign
Cerebral tumor or communicating 
hydrocephalus on neuroimaging
Negative response to large doses of 
levodopa (malabsortion excluded)
Exposure to known neurotoxin (e.g. MPTP)
Unilateral onset
Rest tremor
Progressive disorder
Persistent asymmetry affecting side of onset most
Excellent response (70–100%) to levodopa
Severe levodopa-induced chorea
Levodopa response for ≥5 y
Clinical course of ≥10 y
PD: Parkinson’s disease; MPTP: 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine; y: years; (a)Delayed onset of voluntary movement with increasing reduction of 
amplitude and speed of repetitive movements; (b)Unrelated to primary visual, cerebellar, vestibular or proprioceptive dysfunction.
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On examination, there was mild rest tremor affecting the 
left hand, in addition to moderate bradykinesia, especially 
for finger tapping. The cranial nerves, muscle strength, deep 
tendon reflexes, sensory function, coordination and gait were 
normal. There were no rigidity or postural instability.
Blood tests, including complete blood count, electrolytes 
panel, thyroid function, liver function and hormone levels, 
were normal. Brain MRI showed a hyperintense T2/FLAIR 
image close to the right putamen, indicative of lacunar isch-
emic lesion. Cervical spine MRI was normal.
A therapeutic trial with piribedil and bupropion brought 
partial improvement, leaving her clinically stable for about 
a year, when some degree of motor worsening was noticed. 
Ropinerole was started. Two months later, during a follow-
up clinical examination, slight residual motor impairment 
was detected and it responded partially to adjustments in 
daily dose of ropinerole during the next ten months. Due to 
doubt in clinical diagnosis, she underwent a [99mTc]-TRO-
DAT-1 SPECT scan, showing no significant changes (Fig 2A). 
She was withdrawn of the dopaminergic treatment and on 
follow-up after 6.5 years she is taking only antidepressants. 
Symptoms improved progressively, with no evidence of any 
of the signs of PK.
Case 2
A 63-year-old female was sent for assessment by her oto-
laryngologist due to a hand tremor. Her right hand rest trem-
or was first noticed two years before and progressed slow-
ly, affecting also the contralateral limb. This symptom was 
exacerbated by anxiety and also worsened during the day. 
She had been using flunarizine intermittently for about four 
years to control symptoms of vertigo. Her previous medical 
and family history were unremarkable. On examination, the 
Dix-Hallpike maneuver elicited a mild nystagmus with the 
fast component directed to the right side. Motor examina-
tion showed a mild right asymmetric rest tremor in the upper 
limbs, completely abolished with action. Minimal bradykine-
sia was detected only on the right hand with repetitive move-
ments. Arm swing was symmetric.
The laboratory evaluation showed TSH levels of 6.05 (nor-
mal 4.0). Brain MRI was unremarkable.
The patient was advised to stop flunarizine and treat-
ed with clonazepam and levothyroxine. There was minimal 
improvement after six months and levodopa/benserazide 
100/25 mg/day was started with moderate response. Dosage 
was adjusted, remaining on a plateau of clinical manifesta-
tions that lasted until the 11th year of the follow-up. During 
this period, the patient suffered from anxiety disorder and 
panic attacks, refractory to clonazepan and fluoxetine. These 
symptoms only responded to venlafaxine 150 mg/day. The 
limited motor improvement with significant emotional com-
ponent encouraged the study with [99mTc]-TRODAT-1 SPECT 
scan that showed no abnormalities (Fig 2B). Dopaminergic 
treatment was gradually withdrawn and until the most re-
cent follow-up visit, 14 years after the first motor symptom, 
the patient was using only antidepressants, remaining with a 
slight rest tremor and bradykinesia in her left hand.
Case 3
A 56-year-old female was referred by her general prac-
titioner because of slowness of voluntary movements and 
tremor. Her symptoms started on the left hand four months 
previously. She also complained of a depressed mood and 
mental slowness. All symptoms begun three weeks before 
she underwent a bariatric surgery. Family medical history 
was unremarkable.
General examination showed no significant findings ex-
cept for obesity. The motor examination showed left upper 
limb rest tremor, rigidity and bradykinesia.
The laboratory exams and brain MRI were normal.
The initial treatment included levodopa and paroxetine. 
Four weeks later, she reported mild motor improvement that 
led to a progressive increase of the levodopa dose. After 12 
months, there were no additional motor or non-motor symp-
toms, and the PK remained stable steady improvement, 
worsening with emotional stress only. Due to diagnostic un-
certainty, a [99mTc]-TRODAT-1 SPECT scan was performed, 
showing reduced tracer uptake in the striatum, more pro-
nounced on the right side (Fig 2C). During the latest clinical 
follow-up, after three years of disease, her hand tremor was 
worse and now mild postural instability and motor fluctua-
tion with wearing-off periods were noticed, requiring further 
adjustments of dopaminergic therapy to levodopa/bensera-
zide 100/25 mg/day.
Case 4
A 37-year-old female was assessed by an orthopedic 
surgeon and a general practitioner complaining of tremor. 
Fifteen days before her initial evaluation, the patient noticed 
rest tremor and difficulties with fine movements of the right 
hand. A levodopa trial was stopped as there was no evident 
response. She had suffered from postpartum thyroiditis only. 
The only known relative with a neurologic problem was her 
father in law who suffered from PD. On examination, there 
was a reduction in mobility of the right hand, accompanied 
by moderate rest tremor that left the extremity in an almost 
fixed flexed posture. Right hand bradykinesia was evident on 
clinical examination.
Laboratory tests were normal. Brain MRI showed no 
structural abnormalities.
She was instructed to restart and remain on levodo-
pa aiming to reach higher doses than previously tried. 
During the initial seven months of follow-up, there was lit-
tle improvement in rest tremor, and motor function re-
mained unchanged despite the addition of selegiline to the 
drug regimen. Due to diagnostic uncertainty, a study with 
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Table 2. Clinical and radiological findings of four cases of parkinsonian syndromes initially referred to our movement disorders 
service as Parkinson’s disease cases.
Case Age of onset (y) Duration (y)
Motor signs Addl.
signs
[99mTc]-TRODAT-1 
SPECT Final diagnosisB R T P
1 59 6.5 + + - - - Normal Vascular Parkinsonism
2 61 14 + - + - - Normal Anxiety disorder + Benign Tremulant Parkinsonism
3 56 4 + + + + - Abnormal PD
4 37 2 + - + - Dystonia Normal Dystonic tremor
B: bradykinesia; R: muscle rigidity; T: rest tremor; P: postural instability; PD: Parkinson’s disease; y: years.
Fig 2. Case-illustrative images of dopamine transporter scan 
assessed with TRODAT-1 SPECT: (A) case 1, (B) case 2, (C) case 
3 and (D) case 4. Only the third image is abnormal, showing 
most prominent reduced striatal uptake of the 99Tc-TRODAT 
radiopharmaceutical (contralateral to the worse clinical side-
affected: left arm).
A B
C D
[99mTc]-TRODAT-1 SPECT scanning was performed, showing 
no abnormalities (Fig 2D). A summary of the clinical picture 
and final diagnosis are presented in Table 2.
DISCUSSION
We present our experience with the use of functional im-
aging for the differential diagnosis of cases of PK. It is impor-
tant to stress that during clinical evaluations performed by 
neurologists and non-neurologists, from the beginning of 
motor symptoms to the final diagnosis, PD was considered 
at some point in all cases. Prospective clinical evaluation al-
lowed to establish PD as the etiology of case 3, and this was 
only possible by means of functional imaging with [99mTc]-
TRODAT-1 SPECT scan. The remaining three cases were 
characterized by a more benign course, with features that 
challenged the initial diagnosis of PD, and a normal [99mTc]-
TRODAT-1 SPECT scan, consistent with the recently de-
scribed clinical cases of SWEDDs12-14.
Recent clinical trials aimed to verify the effects of dopa-
minergic therapy in the clinical course of PD and employed 
functional neuroimaging. The ELLDOPA study used the 
tracer [123I]-β-CIT in a subgroup of patients and it showed 
that 21 of the 142 individuals who underwent the examina-
tion (14.7%) showed a putaminal uptake greater than 75% of 
the age-expected putaminal uptake11. The REAL-PET study 
employed 18F-dopa PET and identified 21 cases with nor-
mal scans among 186 randomized subjects (11.3%)10. The 
CALM-PD-CIT study revealed 4% of normal scans8,9. These 
studies speculated the possibility that these patients with 
normal neuroimaging represented either PD cases (possibly 
early stages) or another condition, such as essential tremor 
(ET). This intriguing group of patients has since been de-
scribed as SWEDDs.
Some facts reinforce the idea that SWEDDs differ 
from PD cases. Schneider and colleagues described ten 
SWEDDs patients and proposed that all individuals in 
their series had, in fact, dystonic tremor. Some features 
were consistent with that: the presence of head tremor, 
dystonic posturing of the tremulous limb or thumb ex-
tension tremor, “flurries” or position/task specificity of 
tremor, involvement of neck and speech by dystonia, no 
development of additional features and absence of clear 
akinesia13. The benign clinical and radiological evolution, 
compared to PD, has also been described by other au-
thors14,15. The case 4 described here resembles the patients 
included in the series of Schneider et al.13. Actually, based 
on their clinical characteristics, SWEEDs patients could 
be classified into two major groups: tremor dominant and 
non-tremor dominant SWEDDs, and for each group one 
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may identify the main underlying diagnosis. If one believes 
this is a distinct group of patients, thus clinical classifica-
tion could be a first step to address management.
Studies that focused on non-motor symptoms are inter-
esting approaches to address the differential diagnosis of PD 
versus SWEDDs. Hyposmia occurs in 80–100% of cases of 
PD16,17 and it may represents an initial symptom of the dis-
ease process6,18. The use of the “Sniffin’ Sticks” odor-identi-
fication test resulted in a sensitivity of 88.2 and 63.2% with 
a specificity of 85.7 and 78.6% for early-onset and late-onset 
PD, respectively19. When the University of Pennsylvania Smell 
Identification Test (UPSIT) was used in 21 patients with 
SWEDDs, their scores were significantly higher (better) than 
those of the PD group and did not differ from control, ET or 
dystonia groups16. A low score would indicate a high proba-
bility of PD (accuracy of 97%) and higher UPSIT scores en-
courage the search for alternative diagnoses.
On the other hand, the motor symptoms of SWEDDs cas-
es have been elegantly evaluated by Mian and colleagues us-
ing position markers20. Some aspects differ between PD and 
SWEDDs, lacking in the latter: flexed trunk and elbow angle, 
excessive variability of stride length and altered stepping-
phase coordination. In addition, some findings, not charac-
teristic of ET, were identified in the SWEDDs group: reduced 
arm swing and absence of gait ataxia20.
It is relevant to remember that there are unclear SWEDDs 
cases responsive to levodopa. Sixel-Döring et al. showed 12 
SWEDDs cases (14% of the sample) and 6 of them were re-
sponsive to levodopa. One patient was appointed to have 
dystonic tremor21.
The clinical and paraclinical data on SWEDDs suggest 
that it is not a subtype of PD. Likewise, clinical and neuro-
physiological substrates identified so far seem to differ be-
tween SWEDDs from ET. On the other hand, several of the 
fully described cases of tremulant SWEDDs end up satisfying 
criteria for what is considered dystonic tremor. However, due 
to the lack of histopathological data and a specific marker for 
either condition, except for PD, a define link is still missing.
Our final questions are: what is the role of DAT-SPECT 
in the management of patients with parkinsonism and is it 
cost-effective? Retrospective clinical and pathological stud-
ies have shown that the clinical diagnosis of PD has a sen-
sitivity of 65–99% and a specificity of 8-86% depending on 
the familiarity of the professional with the potential diagno-
ses and the number of manifested parkinsonian signs1. This 
picture improves when strict diagnostic criteria are used at 
movement disorders services, reaching a sensitivity of 91.1% 
and a specificity of 98.4%5.
The rationale for striatal DAT imaging is that this al-
lows in vivo assessment of striatal dopaminergic function 
in patients with PK. The main SPECT tracers currently 
used are [123I]-FP-CIT, [123I]-β-CIT and [99mTc]-TRODAT-1. 
Basically, the semi-quantitative imaging analysis is based 
on the placement of Regions of Interest (ROI) in the stria-
tum, which enables to identify DAT density or DAT avail-
ability. There is a known gradient of dopaminergic dysfunc-
tion that comprehends primarily the putamen contralateral 
to the affected limb and later involvement of the ipsilateral 
caudate22. The European Association of Nuclear Medicine 
Neuroimaging Committee has published guidelines on the 
use of [123I]-β-CIT and [123I]-FP-CIT SPECT23. The techne-
tium-99m labeled TRODAT-1 is a less expensive and more 
available tracer than the iodine-123 labeled radiotracers. 
Its use for the evaluation of clinically unclear parkinsonian 
syndromes has been demonstrated previously, with a sen-
sitivity and specificity of 100 and 70%, respectively, and an 
accuracy of 80%, when it was compared to the last clinical 
diagnosis performed with an average of two years after the 
baseline evaluation24.
In clinical practice, DAT-SPECT or PET provides a pow-
erful tool to demonstrate processes that implicate loss of 
dopaminergic nerve terminals, such as PD, multiple sys-
tem atrophy (MSA), progressive supranuclear palsy, corti-
cobasal degeneration and dementia with Lewy bodies, al-
though it is not useful in their differential diagnosis. When 
faced with a case of PK, but with normal DAT-SPECT, one 
must consider other conditions, including ET, psychogen-
ic, vascular and drug-induced parkinsonism, as well as do-
pa-responsive dystonia25. Hence, from the imaging point of 
view, one should differentiate those patients with and with-
out dopaminergic deficits, and keep in mind that there is a 
clear cut between groups, but not within groups. To illus-
trate this, the sensitivity to differentiate PD from ET using 
DAT imaging may be of 93%26, while in PD versus MSA it is 
much less reliable27. Indications for the use of DAT-SPECT 
were previously published. According to the NICE criteria2, 
the [123I]-FP-CIT SPECT should be: (1) considered for cases 
with tremor in which ET cannot be clinically differentiated 
from parkinsonism and (2) available to specialists with ex-
pertise in its use and interpretation. The indications from 
the European Association of Nuclear Medicine guidelines 
are available in Table 323.
Finally, regarding cost-effectiveness, Van Laere and col-
leagues, using a pharmacoeconomic model in the Belgian 
public health context, studied the economic validity of 
[123I]-FP-CIT in the differential diagnosis of ET and neuro-
degenerative parkinsonism presuming a follow-up of five 
years28. The initial investment of € 900/patient resulted in 
an additional 1.198 “adequately treated years” (ATY). After 
the five years period, the cost difference between the cas-
es handled with DAT-SPECT and those diagnosed solely on 
clinical assessment grounds, would fall to € 429/patient. 
With an estimated prevalence of 60% of neurodegenerative 
parkinsonism, it would mean a small additional cost of € 
358/ATY. Using the same model to the Italian public health 
reality, the use of [123I]-FP-CIT SPECT adds 1.8 ATY at a cost 
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Table 3. European Association of Nuclear Medicine indications for DAT SPECT studies using 123-iodine-labeled 
radiopharmaceuticals.
Indications Potential indications Contraindications
[123I]FP-CIT imaging is indicated for patients 
with CUPS:
•	 It	helps	differentiate	ET	from	parkinsonian	
syndromes related to PD, MSA and PSP.
•	 On	its	own,	it	is	unable	to	discriminate	
between them.
[123I]FP-CIT imaging is indicated for the 
differentiation of DLB from other dementias.
Establishment of early diagnosis of 
neurodegenerative Parkinsonism.
Assessment of disease severity.
Differentiating patients with presynaptic 
PK from those with other forms of PK (e.g. 
between PD and neuroleptic-induced PK).
Pregnancy.
Breast feeding: mothers should interrupt 
breast feeding for 24h if SPECT is indicated.
Inability to cooperate with the procedure.
CUPS: clinically uncertain parkinsonian syndromes; ET: essential tremor; PD: Parkinson’s disease; MSA: multiple system atrophy; PSP: progressive supranuclear 
palsy; DLB: dementia with Lewy bodies; PK: parkinsonism.
1. Litvan I, Bhatia KP, Burn DJ, et al. SIC Task Force appraisal of 
clinical diagnostic criteria for parkinsonian disorders. Mov Disord 
2003;18:467-486.
2. National Collaborating Centre for Chronic Conditions. 
Parkinson’s disease: National clinical guideline for diagnosis 
and management in primary and secondary care. London: Royal 
College of Physicians; 2006.
3. Pankratz ND, Wojcieszek J, Foroud T (Updated July 9, 2009). Parkinson 
disease overview. In: GeneReviews and GeneTests: Medical Genetics 
Information Resource (database online). Copyright, University of 
Washington, Seattle, 1997-2011. Available at: http://www.genetest.
org. [cited 2011 November 8].
4. Munhoz RP, Werneck LC, Teive HAG. The differential diagnoses of 
parkinsonism: findings from a cohort of 1528 patients and a 10 
years comparison in tertiary movement disorders clinics. Clin Neurol 
Neurosur 2010;112:431-435.
5. Hughes AJ, Daniel SE, Ben-Shlomo Y, Lees AJ. The accuracy of 
diagnosis of parkinsonian syndromes in a specialist movement 
disorder service. Brain 2002;125:861-870.
6. Braak H, Tredici KD, Rüb U, de Vos RAI, Steur ENHJ, Braak E. Staging 
of brain pathology related to sporadic Parkinson’s disease. Neurobiol 
Aging 2003;24:197-211.
7. Brooks DJ. Imaging approaches to Parkinson disease. J Nucl Med 
2010;51:596-609.
8. Parkinson Study Group. Dopamine transporter brain imaging to 
assess the effects of pramipexole vs levodopa on Parkinson disease 
progression. JAMA 2002;287:1653-1661.
9. Parkinson Study Group. A randomized controlled trial comparing 
pramipexole with levodopa in early Parkinson’s disease: design 
and methods of the CALM-PD Study. Clin Neuropharmacol 
2000;23:34-44.
10. Whone AL, Watts RL, Stoessl AJ, et al. Slower progression of 
Parkinson’s disease with ropinirole versus levodopa: the REAL-PET 
Study. Ann Neurol 2003;54:93-101.
11. Fahn S, Oakes D, Shoulson I, et al. Levodopa and the progression of 
Parkinson’s disease. N Engl J Med 2004;351:2498-2508.
12. Fahn S, and the Parkinson Study Group. Does levodopa slow or 
hasten the rate of progression of Parkinson’s disease? J Neurol 
2005;252:IV37-IV42.
13. Schneider SA, Edwards MJ, Mir P, et al. Patients with adult-onset dystonic 
tremor resembling parkinsonian tremor have scans without evidence od 
dopaminergic deficit (SWEDDs). Mov Disord 2007;22:2210-2215.
14. Marek K, Jennings D, Seibyl J. Long-term follow-up of patients with 
scans without evidence of dopaminergic deficit (SWEDDs) in the 
ELLDOPA study. Neurology 2005;64(Suppl 1):S274.
15. Bain PG. Dystonic tremor presenting as parkinsonism: long-term 
follow-up of SWEDDs. Neurology 2009;72:1443-1445.
16. Silveira-Moriyama L, Schwingenschuh P, O’Donnell A, et al. Olfaction 
in patients with suspected parkinsonism and scans without evidence 
of dopaminergic deficit (SWEDDs). J Neurol Neurosurg Psychiatry 
2009;80:744-748.
17. Doty RL. Olfaction in Parkinson’s disease. Parkinsonism Relat Disord 
2007;13(Suppl):S225-S228.
18. Lim S, Lang AE. The nonmotor symptoms of Parkinson’s disease – an 
overview. Mov Disord 2010;25(Suppl 1):S123-S130.
19. Santin R, Fonseca VF, Bleil CB, Rieder CRM, Hilbig A. Olfactory function 
and Parkinson’s disease in Southern Brazil. Arq Neuropsiquiatr 
2010;68:252-257.
20. Mian OS, Schneider SA, Schwingenschuh P, Bhatia KP, Day BL. Gait in 
SWEDDs patients: comparison with Parkinson’s disease patients and 
healthy controls. Mov Disord 2011;26:1266-1273.
References
saving of € 442 per patient. This favorable cost-benefit ratio 
remains with a prevalence of neurodegenerative parkinson-
ism of up to 55%29. Therefore, in the context of European 
public health service, the use of DAT-SPECT could save 
resources and keep patients with PK on proven beneficial 
therapy over a longer period. The use of the least expensive 
and more available [99mTc]-TRODAT-1 has the potential to 
further reduce the cost-benefit ratio.
In conclusion, challenging movement disorders are not 
uncommon. This becomes even more relevant when the 
patient presents at an early stage of the disease process 
without the most striking manifestations of the parkin-
sonian syndrome. For these cases, the use of DAT-SPECT 
shows some promising clinical and economical advantag-
es. With the more widespread use of this technology, the 
SWEDDs cases will become more common in routine clin-
ical practice. Current literature suggests they are different 
from PD cases and have a better prognosis. However, de-
tails about their management and histopathology remain 
to be clarified.
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